HUTCHMED will use next week’s oncology meetings to surface a broad slate of lung and solid tumor readouts, led by updated analyses for savolitinib in MET-driven non-small cell lung cancer at WCLC and a first-in-human presentation for its CSF-1R inhibitor HMPL-653 in tenosynovial giant cell tumor at CSCO. The savolitinib package encompasses biomarker concordance and acquired resistance from SAVANNAH, patient-reported outcomes from the osimertinib plus savolitinib combination in EGFR-mutant disease with MET overexpression and/or amplification, insights into treatment duration from the SACHI study after third-generation EGFR TKI failure, and confirmatory Phase IIIb data in NSCLC. Additional WCLC material examines savolitinib in MET exon 14 skipping NSCLC with or without prior immunotherapy. At CSCO, the company augments its pipeline signal-hunting through multiple investigator-initiated combinations of fruquintinib and surufatinib across gastrointestinal, hepatobiliary, pancreatic, neuroendocrine, and small cell lung cancers.
The emphasis in Barcelona is clear: refine and defend savolitinib’s role across MET biology while strengthening the evidentiary spine behind combination use after osimertinib progression. Biomarker concordance and resistance profiling indicate that HUTCHMED and AstraZeneca are working to codify who benefits and why, a prerequisite as regulators and payers increasingly require reproducible assay strategies and consistent cutoffs for MET amplification or overexpression beyond METex14. The inclusion of patient-reported outcomes suggests a parallel value narrative aimed at tolerability and quality-of-life claims that can matter in crowded lines of therapy. The Phase IIIb “confirmatory” label signals regulatory follow-through in China for previously granted pathways, while the METex14 dataset, which stratifies by prior immunotherapy exposure, targets practical adoption questions clinicians face in later lines.
This is a defensive and expansion play at once. Defensively, MET-targeted NSCLC has become competitive as other inhibitors and EGFR/MET combination strategies mature. Differentiation will likely hinge less on headline response rates and more on operational clarity, including validated diagnostics, manageable toxicity in combination with EGFR TKIs, and clear resistance maps that simplify sequencing. Expansion-wise, the company is laying the groundwork for a broader combination positioning with osimertinib and potentially earlier use if biomarker-driven enrichment can be refined. The breadth of CSCO investigator-initiated trials around fruquintinib and surufatinib underscores a portfolio approach that seeds low-cost signals across indications and regimens, creating optionality for sponsor-led randomized programs if data cohere.
For sites and CROs, the savolitinib agenda elevates assay logistics and timing. Programs that require MET amplification or overexpression post-osimertinib will strain tissue availability and increase reliance on ctDNA; concordance analyses hint at an effort to harmonize tissue and liquid biopsy workflows, but execution will come down to central lab contracts, turnaround times, and strict post-progression sampling windows. Investigator-initiated combinations introduce added safety monitoring and drug–drug interaction management at community and academic centers. In contrast, PRO collection in combination trials raises the bar on eCOA readiness and compliance. Regulators will be watching for consistent biomarker definitions and durability signals in confirmatory settings. In parallel, HMPL-653’s entry into TGCT steps into a class where hepatic safety has framed the risk–benefit debate; differentiation on liver function lab profiles and surgical collaboration will be pivotal for site selection and pathway adoption.
What matters next is specificity. If WCLC delivers clear, prospectively usable thresholds for MET positivity and a sampling strategy that aligns across tissue and ctDNA, it could unlock a cleaner registrational path for the osimertinib plus savolitinib combination outside China. The Phase IIIb data will be scrutinized for durability and survival context, not just response. Early HMPL-653 signals should be read for safety headroom and translational markers that support dose selection. From CSCO, watch which fruquintinib and surufatinib combinations show reproducible activity worth advancing into controlled studies. Risks are familiar: biomarker ambiguity that slows enrollment or blunts effect size, confirmatory outcomes that fail to extend duration or survival, and intensifying competition from other MET strategies. Clarity on companion diagnostic partnerships and global site footprint build-out will indicate how quickly any positive signals can move toward registrational execution.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
